- Report
- November 2024
- 150 Pages
Global
From €5342EUR$5,950USD£4,549GBP
- Report
- May 2025
- 184 Pages
Global
From €3183EUR$3,545USD£2,711GBP
€3537EUR$3,939USD£3,012GBP
- Report
- March 2025
- 200 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- April 2025
- 200 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- June 2025
- 84 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Clinical Trials
- April 2025
- 280 Pages
Global
From €2694EUR$3,000USD£2,294GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1796EUR$2,000USD£1,529GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1796EUR$2,000USD£1,529GBP
- Report
- March 2025
- 130 Pages
Global
From €3919EUR$4,365USD£3,337GBP
€4355EUR$4,850USD£3,708GBP
- Report
- July 2024
- 150 Pages
Global
From €5342EUR$5,950USD£4,549GBP
- Report
- January 2025
- 175 Pages
Global
From €4031EUR$4,490USD£3,433GBP
- Report
- March 2025
- 150 Pages
Global
From €2918EUR$3,250USD£2,485GBP
€4355EUR$4,850USD£3,708GBP
- Report
- January 2025
- 492 Pages
Global
From €8974EUR$9,995USD£7,642GBP
- Report
- July 2024
- 101 Pages
Africa, Middle East
From €3098EUR$3,450USD£2,638GBP
- Report
- July 2024
- 108 Pages
Europe
From €3098EUR$3,450USD£2,638GBP
- Report
- July 2024
- 107 Pages
North America
From €3098EUR$3,450USD£2,638GBP
- Report
- May 2022
- 95 Pages
Global
From €1437EUR$1,600USD£1,223GBP
- Report
- December 2020
- 193 Pages
Global
From €4444EUR$4,950USD£3,785GBP
- Report
- January 2022
- 133 Pages
Global
From €4938EUR$5,500USD£4,205GBP
- Report
- June 2024
- 137 Pages
Global
From €5342EUR$5,950USD£4,549GBP

The Osteoarthritis Drug market is a subset of the larger Musculoskeletal Disorders Drugs market. Osteoarthritis is a degenerative joint disease that affects millions of people worldwide. It is characterized by the breakdown of cartilage in the joints, leading to pain, stiffness, and decreased mobility. Treatment for osteoarthritis typically involves a combination of lifestyle changes, physical therapy, and medications. Common medications used to treat osteoarthritis include non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, and disease-modifying antirheumatic drugs (DMARDs).
The Osteoarthritis Drug market is highly competitive, with a variety of companies offering products to treat the condition. Some of the major players in the market include Pfizer, Merck, Novartis, AbbVie, and Johnson & Johnson. Other companies such as Amgen, Eli Lilly, and Bristol-Myers Squibb also offer products for the treatment of osteoarthritis. Show Less Read more